Article Text

Checkpoint inhibitor-associated immune arthritis
  1. Laurent Arnaud1,
  2. Bénédicte Lebrun-Vignes2,
  3. Joe-Elie Salem2
  1. 1Department of Rheumatology, Hôpitaux Universitaires de Strasbourg & INSERM UMRS-1109, Strasbourg, France
  2. 2AP-HP, Pitié-Salpêtrière Hospital, Department ofPharmacology, CIC-1421, Pharmacovigilance Unit ; INSERM, UMR ICAN 1166;Sorbonne Universités, UPMC Univ Paris 06, Faculty of Medicine; Institute ofCardiometabolism and Nutrition (ICAN), F-75013, Paris, France
  1. Correspondence to Professor Laurent Arnaud, Department of Rheumatology Hôpitaux Universitaires de Strasbourg & INSERM UMRS-1109 Strasbourg France ; laurent.arnaud{at}

Statistics from

We read with interest the paper by Kostine et al.1 Immune checkpoint inhibitors (ICIs) have dramatically improved clinical outcomes in various cancer types and are increasingly being used in earlier disease settings and in combination.2 The main targets of ICIs, programmed cell death 1 (PD-1) and its ligand PD-L1 as well as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) are involved in downregulating autoimmunity, with PD-1-deficient C57BL/6 mice exhibiting lupus-like features and CTLA-4 enabling Treg suppression of autoreactive T cell activation.3 It was therefore no surprise that immune-related adverse events (irAEs) such as immune arthritis, rheumatoid arthritis or systemic lupus …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles